METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VLLL THERAPY

• Main Authors: TONGYAO LIU, NEIL JOSEPHSON, HAIYAN JIANG, PIERCE GLENN, SRIRAM KRISHNAMOORTHY
• Format: Patent
• Language: Chinese; English
• Published: 31.08.2018
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprisefull-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain. 本公开提供向处于产生包括抗FVIII抗体和/或细胞介导的免疫性的抑制性FVIII免疫反应的风险下的受试者施用包含FVIII和Fc的嵌合和杂交因子VIII(FVIII)多肽的方法。所述施用足以促进凝血且诱导对FVIII的免疫耐受性。所述嵌合多肽可包含全长FVIII或含有缺失，例如B结构域的完全或部分缺失的FVIII多肽。